Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TJ004309 alone and with toripalimab in advanced solid tumors
CTR20200445Phase 2Completed
- Sponsor
- I-Mab
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of uliledlimab in Nonhematologic neoplasms, sponsored by I-Mab. Started May 2020; status: completed.
02
Drugs
uliledlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20200445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200445.